#Firstpost LIVE: Indian Pharma Faces Heat as Trump Slaps 100% Tariff on Drug Imports | N18G

LIVE: Indian Pharma Faces Heat as Trump Slaps 100% Tariff on Drug Imports | N18G
President Trump has opened a new front in his trade war — this time targeting pharmaceuticals. From October, branded and patented drug imports will face a 100% tariff in the U.S. India, America’s biggest supplier of medicines, will feel the heat. Generics are exempt — for now — but Washington has launched a sweeping investigation into pharma imports, raising fears of wider restrictions. Indian companies, which supply nearly one-third of U.S. medicines, may face pressure to “Make in America” — build factories, hire locally, and absorb higher costs. Markets across Asia reacted sharply, with pharma stocks sliding. The risk is clear: Indian pharma could lose competitiveness, and American patients may end up paying higher prices for essential, even life-saving drugs.

Follow Firstpost on WhatsApp:
https://ift.tt/UKq9wPW

Thank you for your support in keeping this website running.💛

View on “Tokyo Trend News”